Rallybio Revenue

In the year 2025, Rallybio had annual revenue of $858.00K with 34.91% growth. Rallybio had revenue of $222.00K in the quarter ending December 31, 2025, with 484.21% growth.

Revenue (ttm)

$858.00K

Revenue Growth

+34.91%

P/S Ratio

50.62

Revenue / Employee

$61,286

Employees

Market Cap

43.43M

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	858.00K	222.00K	34.91%
Dec 31, 2024	636.00K	-	-
Dec 31, 2023	-	-	-
Dec 31, 2022	-	-	-
Dec 31, 2021	-	-	-
Dec 31, 2020	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2019	Upgrade Pro	Upgrade Pro	Upgrade Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Celularity	40.58M
Veru Inc.	16.89M
Immutep	5.28M
RenovoRx	1.12M
Lisata Therapeutics	170.00K

Revenue Rankings

RLYB News

5 weeks ago - Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism - Benzinga
5 weeks ago - Rallybio Corporation and Candid Therapeutics Announce Merger Agreement - Business Wire
7 weeks ago - Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026 - Benzinga
7 weeks ago - Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement - Business Wire
2 months ago - Rallybio Announces Reverse Stock Split of Common Stock - Business Wire
5 months ago - Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates - Business Wire
7 months ago - Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study - Business Wire
7 months ago - Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program - Business Wire

More News